Search research articles
Contact Us
Filters
Showing results (1-10 of 44) with videos related to
Page
of 5
Sort By:
Pharmacoeconomics
|
February 25, 2022
Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
Chris Skedgel
Pharmacoeconomics
|
December 22, 2021
Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
Chris Skedgel
Social Science & Medicine (1982)
|
July 2, 2005
Cross-district utilization of general hospital care in Nova Scotia: policy and service delivery implications for rural districts
Neil Hanlon, Chris Skedgel
Pharmacoeconomics
|
April 21, 2011
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial
Tallal Younis, Chris Skedgel
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 10, 2010
Is trastuzumab a cost-effective treatment for breast cancer?
Tallal Younis, Chris Skedgel
The Patient
|
July 21, 2014
Constant-sum paired comparisons for eliciting stated preferences: a tutorial
Chris Skedgel, Dean A Regier
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 21, 2026
Discounting shortfall, increasing barriers: pragmatic objections to discounting shortfall in NICE's severity modifier
Chris Skedgel, David J Mott
Applied Health Economics and Health Policy
|
June 18, 2021
Towards a New Understanding of Unmet Medical Need
Kyann Zhang, Gayathri Kumar, Chris Skedgel
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
August 23, 2014
Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment
Chris Skedgel, Allan Wailoo, Ron Akehurst
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 18, 2015
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Chris Skedgel, Daniel Rayson, Tallal Younis
Page
of 5
Search research articles
Search
Showing results (1-10 of 44) with videos related to
Sort By:
Page
of 5
Pharmacoeconomics
|
February 25, 2022
Correction to: Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
Chris Skedgel
Pharmacoeconomics
|
December 22, 2021
Dramatic Innovations in the Treatment of Spinal Muscular Atrophy, But Many Unknowns Remain
Chris Skedgel
Social Science & Medicine (1982)
|
July 2, 2005
Cross-district utilization of general hospital care in Nova Scotia: policy and service delivery implications for rural districts
Neil Hanlon, Chris Skedgel
Pharmacoeconomics
|
April 21, 2011
Adjuvant trastuzumab for breast cancer: uncertainties in clinical and economic evidence following early stopping of the HERA trial
Tallal Younis, Chris Skedgel
Expert Review of Pharmacoeconomics & Outcomes Research
|
June 10, 2010
Is trastuzumab a cost-effective treatment for breast cancer?
Tallal Younis, Chris Skedgel
The Patient
|
July 21, 2014
Constant-sum paired comparisons for eliciting stated preferences: a tutorial
Chris Skedgel, Dean A Regier
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research
|
June 21, 2026
Discounting shortfall, increasing barriers: pragmatic objections to discounting shortfall in NICE's severity modifier
Chris Skedgel, David J Mott
Applied Health Economics and Health Policy
|
June 18, 2021
Towards a New Understanding of Unmet Medical Need
Kyann Zhang, Gayathri Kumar, Chris Skedgel
Medical Decision Making : an International Journal of the Society for Medical Decision Making
|
August 23, 2014
Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment
Chris Skedgel, Allan Wailoo, Ron Akehurst
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer
|
June 18, 2015
Is febrile neutropenia prophylaxis with granulocyte-colony stimulating factors economically justified for adjuvant TC chemotherapy in breast cancer?
Chris Skedgel, Daniel Rayson, Tallal Younis
Page
of 5